TABLE OF CONTENTS

A. EXECUTIVE SUMMARY
B. MARKET DATA
C. HIGH-IMPACT STORIES (5)
D. MODERATE-IMPACT STORIES (8)
E. ECONOMY WATCH (5)
F. EARNINGS WATCH (4)
G. WHAT’S NEXT
H. CHART OF THE DAY

A. EXECUTIVE SUMMARY -> TOP

B. MARKET DATA -> TOP

Wall Street closed little changed Wednesday as investors weighed hotter-than-expected headline PCE inflation (3.7% YoY) against anticipation of Nvidia’s after-the-bell report, with the S&P 500 (-0.02%) and Dow (-0.21%) essentially flat while the Nasdaq 100 (+0.05%) and DJ Transports (+0.59%) posted modest gains. Sector action was narrow and directionless — Industrials led (+0.98%) while Basic Materials lagged (-1.24%) despite its 39.6% 12-month gain, and healthcare names sold off broadly (Eli Lilly -3.59%, Merck -2.14%) on no fresh company-specific news. Tech and industrial names topped the mega-cap board — Arista (+5.92%), Oracle (+2.84%), GE Vernova (+2.84%, Korea HVDC joint venture) — keeping the AI-infrastructure trade alive even as bond yields ticked up modestly. Natural gas diverged sharply from crude, with Henry Hub +2.94% against a 3.53% slide in Dutch TTF.

CLOSING PRICES – August 26, 2026:

MAJOR INDICES

Dow Theory bull confirmation remains in force — DJIA and DJTA both sit within 2% of their 10-session highs, with transports outperforming industrials today (+0.59% vs -0.21%). NYSE Composite (-0.11%) and Russell (-0.14%) tracked the blue-chip weakness while Nasdaq 100 (+0.05%) held flat; the tape stayed narrow and directionless as investors digested hotter-than-expected headline PCE ahead of Nvidia’s after-the-bell report.

VOLATILITY & TREASURIES

VIX eased to 15.21 even as yields nudged higher — 10Y +1bp, 2Y +0.5bp — a muted reaction to hotter headline PCE (3.7% YoY) that suggests the inflation print didn’t shift the rate path materially. The dollar firmed alongside the yield move (DXY +0.24%), a conventional pairing rather than a risk-off signal.

COMMODITIES

Precious metals slid in lockstep — gold -0.98%, silver -0.94%, platinum -1.10% — a broad pullback from recent record levels rather than a divergence. Copper’s steeper -1.72% drop hints at a softer industrial-demand read. Bitcoin’s modest +0.29% gain decoupled from the metals rout, tracking equities’ flat tape instead.

ENERGY

WTI and Brent eased in tandem on a modest supply-side pullback — no meaningful spread widening. Natural gas told a different story: Henry Hub jumped 2.94% while Dutch TTF sank 3.53%, a sharp transatlantic divergence pointing to region-specific supply/demand dynamics rather than a broad energy move.

S&P 500 SECTORS

Basic Materials led YTD gains (+22.97%) yet was today’s biggest laggard (-1.24%), a sharp same-day reversal. Communication Services extended its 3-month slide (-8.93%) with another red session, while Industrials — this week’s laggard (-1.16%) — topped today’s board (+0.98%), a reversal worth watching.

TOP MEGA-CAP MOVERS:

GAINERS

DECLINERS

C. HIGH-IMPACT STORIES -> TOP

1. The Market Is Pricing a September HIKE, Not a Cut — and Today’s PCE Print Did Nothing to Take It Off the Table

The core facts:July PCE landed at 8:30 ET with headline inflation a tenth above consensus at 3.7% year-over-year and core in line at 3.3%. The market’s response was almost nothing: the S&P 500 closed -0.02% at 7,675.70, the Dow -0.21%, the Nasdaq 100 +0.05%. The 10-year yield rose one basis point to 4.649% and the 2-year half a point to 4.209%; the dollar index firmed 0.24% to 99.17 and the VIX fell 1.55% to 15.21. Crucially, the policy question priced into fed funds futures is a hike, not a cut — CME FedWatch-implied odds of a 25bp September increase sat near 38% after the print, with the probability of a hike by year-end around 73%. That September figure has been the market’s live variable all month: it stood near 67% on July 31 before the July payrolls miss knocked it down. Section E carries the full data breakdown.

Why it matters:The direction of the risk is the whole point, and it is the opposite of the reflex most portfolios are positioned for. With headline inflation running at nearly double the 2% target and the labour market soft enough to have cut hike odds almost in half this month, the Fed is boxed between a mandate it is missing badly and an economy that cannot obviously absorb tightening. That is why a hot print produced a one-basis-point move: the tape has already stopped trading each release as a directional signal and is waiting for the person who decides. Friday is the first genuine information event — Kevin Warsh’s inaugural Jackson Hole keynote as chair, at 10:00 ET, with no Powell-style forward-guidance framework yet established to anchor expectations. A BofA fund-manager survey has 69% expecting a neutral tone, which is precisely the setup in which a hawkish surprise repriced the front end hardest. The muted reaction today is not calm; it is deferred risk.

What to watch:Warsh’s keynote Friday, August 28 at 10:00 ET, and whether September hike probability breaks back above 50% on it. The 2-year yield at 4.209% is the cleanest single read on that repricing.

2. Meta Settles With 29 State Attorneys General for $16.7 Billion — and Accepts a Two-Hour Daily Cap on Teen Accounts for the Next Decade

The core facts:Disclosed in a court filing mid-trial today, Meta will pay $16.7 billion to resolve claims by 29 state attorneys general that it designed Facebook and Instagram to addict minors, improperly captured data from children, and misled the public about platform safety. Reporting places Meta’s aggregate settlement exposure across related matters nearer $18 billion. The case was co-led by California’s Rob Bonta alongside the attorneys general of Colorado, New Jersey and Kentucky. Meta admitted no wrongdoing. The non-monetary terms are the substantive half: for the next ten years Meta will restrict teen use of Facebook and Instagram to two hours per day, block access entirely from midnight, expand parental controls, and raise age-verification standards. Shares traded a 6.5% intraday range — a $561.95 low against a $598.37 high, changing hands near $577 — on volume of 22.5 million against a 14.8 million average, though the close was not large enough to place Meta among the session’s five biggest mega-cap movers.

Why it matters:The cash is affordable and almost beside the point — $16.7 billion is roughly a quarter’s free cash flow for Meta. The decade-long engagement cap is not. A two-hour ceiling and a midnight blackout on the teen cohort is a permanent, court-supervised constraint on impressions in the demographic that seeds every subsequent cohort of users, and it is being imposed on the exact product surface Meta has spent three years defending as a First Amendment and Section 230 matter. That defence has now been traded away for finality. The read-through runs well past Meta: 29 states have just established a template with quantified time limits, and TikTok, Snap and YouTube face substantially the same claims from substantially the same plaintiffs. The market’s difficulty in pricing this — a 6.5% intraday swing that resolved into roughly nothing — is the honest response to a settlement that removes an enormous tail risk and installs a structural revenue drag in the same document.

What to watch:Whether Snap, Pinterest or Alphabet disclose settlement discussions with the same AG coalition, and Meta’s next 10-Q for the first disclosed estimate of the revenue impact from the teen time limits.

3. Crude Broke 3% on a Signed Hormuz Corridor and Round-Tripped the Entire Move on a Bloomberg Report That Putin Is Escalating

The core facts:Iran’s deputy foreign minister for legal and international affairs, Kazem Gharibabadi, confirmed that Tehran and Muscat have agreed a temporary seven-mile (11.3 km) transit corridor through the Strait of Hormuz, with entry and part of the exit running through Iranian territorial waters. Foreign Minister Abbas Araghchi met his Omani counterpart Badr Albusaidi in Tehran on the corridor and on a parallel mine-clearing project; technical talks on a permanent arrangement run 30 to 60 days. The strait does not fully reopen until Washington honours the lapsed June interim deal. Brent broke below $90 overnight and both benchmarks were down roughly 3% intraday. They did not stay there: Bloomberg reported, citing three people close to the Kremlin, that Russia is weighing intensified ballistic-missile attacks on Kyiv having concluded peace talks are exhausted, and crude recovered almost the entire loss into the settle. WTI finished at $81.89 (-0.57%) and Brent at $86.53 (-0.85%). Kpler counted just five commodity vessels transiting Hormuz on Tuesday against a ten-day average of fifteen.

Why it matters:A round trip of that size is more informative than a 3% decline would have been. It says the market will not pay for a Hormuz de-escalation headline while a second, entirely separate supply war is intensifying — and it says the risk premium has migrated from the Gulf to Russia. Note what the corridor actually is: seven miles wide, temporary, routed through Iranian territorial waters, contingent on an American commitment that has already lapsed once, and running at a third of normal transit volume. That is a hostage arrangement with a shipping lane attached, not a reopening, and the tanker count is the tell. Meanwhile the Bloomberg report is single-outlet and rests on unnamed sources — it should be held as a report rather than an established fact — but it moved the complex several dollars, which is itself the tradeable information. For a US portfolio the practical consequence is that crude has stopped being a clean directional expression of Middle East risk; energy closed +0.18% on a session in which the benchmark traded a 3% range.

What to watch:Kpler’s daily Hormuz transit count against the fifteen-vessel ten-day average — a move back toward normal volumes would validate the corridor; continued single-digit counts mean it exists on paper only.

4. America Is Heading for Its First $4 Labor Day on Record — and It Is a Refining Story, Not a Crude Story

The core facts:GasBuddy’s Patrick De Haan said this morning that Americans could for the first time ever face a national average above $4 a gallon on Labor Day, eclipsing the $3.83 record set in 2012. The national average is $4.05 to $4.09 depending on the survey; the EIA independently put it at $4.085 on August 24, up 3.6 cents on the week and 93.8 cents on the year. Diesel is the sharper problem — $5.58 on GasBuddy’s tape and $5.652 on the EIA’s on-highway series, up 19.8 cents in a week and $1.944 on the year, a 52% annual increase. Today’s EIA weekly report put distillate stocks at 103.4 million barrels, roughly 13-14% below the five-year seasonal average, and gasoline at 206.8 million, 6% below. Refineries are already running flat out at 97.4% of operable capacity. Federal forecasters now expect gasoline, diesel and jet stocks to finish the year at their lowest since 2000. The supply side keeps deteriorating: overnight, Ukrainian special operations and unmanned systems forces struck Lukoil’s Nizhegorodnefteorgsintez plant at Kstovo — Russia’s second-largest gasoline producer at roughly 340-350 kb/d and up to 11% of national petrol output — the fifth strike on that single asset this year, amid 426 drones over Russia in one night.

Why it matters:Crude closed down today. Pump prices are at a record for the calendar date anyway, and that disconnect is the entire story: the binding constraint has moved from barrels to the ability to turn barrels into fuel, and refining capacity cannot be conjured on a drone-strike timetable. At 97.4% utilisation the US system has no slack to absorb an outage of its own, which turns every incremental Russian refinery fire into a global products bid. The macro consequence lands directly on the story above — energy is a heavyweight CPI component, headline PCE already printed 3.7%, and a 52% year-on-year move in diesel feeds through freight into goods prices with a lag of months, not weeks. This is the mechanism by which a war 5,000 miles away removes the Fed’s room to cut. It is also a straightforward consumer tax: 94 cents a gallon year-on-year, arriving in the same quarter Pantheon Macro flags the tax-refund cash cushion fading and the Conference Board’s expectations gauge sits below its own recession threshold.

What to watch:Next Wednesday’s EIA distillate number — another draw from 103.4 million barrels with refineries already at 97.4% utilisation would confirm the squeeze is structural, and diesel cracks would follow.

5. The Atlanta Fed’s Q3 Nowcast Turned Back Up to 4.6% Today — and Cleveland’s Says Inflation Is Re-Accelerating Too

The core facts:The Atlanta Fed updated GDPNow today and lifted its Q3 2026 real GDP estimate to 4.6%, from 4.0% on August 18. Per the bank’s own commentary the revision came from consumption and investment together: the Q3 nowcast for real personal consumption expenditure growth rose from 2.5% to 3.1%, and real gross private domestic investment growth from 13.7% to 14.5%. The series had been falling all month — 5.0% on July 30, 6.2% on August 3, 5.9% on August 4, 4.3% on August 14, 4.0% on August 18 — and today it turned. Separately, the Cleveland Fed’s inflation nowcast has August core PCE running at 3.40% year-over-year and CPI at 3.37%, both above the July core PCE of 3.3% that printed this morning. Against this, the BEA’s second estimate confirmed Q2 real GDP at just 1.5%, down from 2.1% in Q1.

Why it matters:Two Reserve Banks’ own models are now pointing at growth and inflation re-accelerating into the September FOMC, which is the single configuration that makes a hike defensible rather than merely feared — and it directly contradicts the consumer-slowdown narrative that Pantheon Macroeconomics, the Conference Board expectations index and this week’s 10.5% new-home-sales collapse have been building. Both cannot be right. The gap between Q2’s confirmed 1.5% and a Q3 nowcast of 4.6% is far too wide to be noise, and the honest reading is that GDPNow is being driven by an investment component running at 14.5% growth that is overwhelmingly AI capital expenditure — the same spending Nvidia quantified after the bell tonight with a supply commitment that more than doubled to $279 billion. That is a real economy with two distinct speeds inside it, and the aggregate statistic the Fed sets policy against averages them into something that describes neither. A portfolio manager should treat 4.6% as a statement about datacentre construction, not about the household sector.

What to watch:The next GDPNow update and whether 4.6% holds or resumes falling; and the August core PCE print in late September against Cleveland’s 3.40% nowcast — a confirmed acceleration above July’s 3.3% would put the September hike back in play decisively.

D. MODERATE-IMPACT STORIES -> TOP

6. Boston Scientific Discloses an Active Cyberattack That Has Stopped It Shipping Customer Orders Worldwide

The core facts:In an 8-K filed today, Boston Scientific said it identified a cybersecurity incident on August 25 affecting certain IT systems that has produced “a global disruption to the Company’s operations.” The filing is unusually specific about the operational reach: the incident has caused, and is expected to continue to cause, disruptions and limitations of access to information systems and business applications supporting the company’s operations, including its ability to process and ship customer orders. Incident-response protocols were activated and third-party cybersecurity experts engaged. The company said the timeline for full restoration is not yet known and that it has not determined whether the incident is likely to have a material effect. Staff at its Cork, Ireland facility were told to work from home. The shares fell as much as 5.8% in premarket trade and were down roughly 4.5% in morning dealing.

Why it matters:The phrase that matters is “process and ship customer orders.” Boston Scientific’s customers are hospitals and cath labs, and its products are pacemakers, defibrillators, stents and ablation catheters that are consumed in scheduled and emergent procedures. An order-fulfilment outage of unknown duration at a company of that scale is not an IT inconvenience; it is deferred revenue that may not be recoverable, because a hospital that cannot get a device this week substitutes a competitor’s rather than postponing the patient. Abbott, Medtronic and Edwards are the direct beneficiaries of every day this runs. The second-order point is that management explicitly declined to assess materiality — standard 8-K language, but it means the quarter is genuinely unquantified with five weeks left in it, and the disclosure landed six days before Medtronic reports on September 1 into the same end market.

What to watch:A follow-up 8-K quantifying materiality, or a company statement confirming order processing has been restored — each day without one raises the probability that Q3 guidance moves.

7. The FDA Approves the First RAS Inhibitor for Pancreatic Cancer, and It Nearly Doubles Median Survival

The core facts:The FDA approved Revolution Medicines’ Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or are not candidates for multiagent therapy. In the randomised open-label Phase 3 RASolute 302 trial of 500 previously treated patients, median overall survival was 13.2 months against 6.7 months for standard chemotherapy — a 60% reduction in the risk of death. The drug requires no companion diagnostic and is approved with or without an identified RAS tumour mutation. It carried Breakthrough Therapy and Orphan Drug designations plus Priority Review, was reviewed under the Commissioner’s National Priority Voucher pilot, and cleared roughly 6.5 months ahead of its PDUFA date. List price is $39,800 per 30-day supply, available immediately. Revolution Medicines’ market capitalisation is $44.77 billion at $208.17 a share.

Why it matters:RAS has been the archetypal undruggable target for four decades and metastatic pancreatic cancer is the disease with the worst survival statistics in oncology, so a first-in-class approval that nearly doubles median survival is a genuine platform validation rather than an incremental label. The commercially decisive detail is the absence of a companion diagnostic — every previously treated metastatic patient is addressable without genotyping, which removes the testing bottleneck that has kept the KRAS G12C franchises (Amgen’s Lumakras, Bristol Myers’s Krazati) confined to single-digit percentages of tumours. That makes this a competitive datapoint against both, and it re-rates the multi-selective RAS(ON) approach relative to mutation-specific inhibitors across the sector. The $39,800 monthly price is a separate story in its own right and will draw payer and PBM attention immediately, particularly given a policy environment already running most-favoured-nation pricing agreements. Also note the regulatory signal: clearance 6.5 months early under the National Priority Voucher pilot tells developers the pathway is real.

What to watch:Amgen and Bristol Myers commentary on Lumakras and Krazati positioning, and the first payer coverage decisions on a $39,800-per-month oncology drug with no diagnostic gate.

8. Salesforce Puts Its Own Sales Stack Inside Anthropic’s Claude and Calls It “Claudeforce” — the First Time It Has Branded Somebody Else’s Product

The core facts:Salesforce and Anthropic expanded their strategic partnership today and launched Claudeforce, a plugin embedding 37 pre-built Salesforce sales skills directly inside Claude — composing emails, updating records and taking CRM actions from within Anthropic’s product rather than Salesforce’s. The companies said further integrations across Claude, Salesforce and Slack will follow. It is the first time Salesforce has applied its “-force” suffix to another company’s product. Marc Benioff framed it as “fusing Claude’s extraordinary reasoning with the trusted data, workflows, and governance every enterprise runs on.” No financial terms were disclosed, so the arrangement cannot be sized. Salesforce separately reported Q2 FY2027 results after the close (Section F), a quarter that included a $2.6 billion gain on strategic investments tied to its Anthropic stake.

Why it matters:Read the direction of travel, because it is the opposite of what the branding suggests. Salesforce is not putting Claude into Salesforce; it is putting Salesforce into Claude, and accepting that the seat a salesperson spends the day in may be Anthropic’s rather than its own. CNBC framed the announcement explicitly as Benioff’s answer to “SaaSpocalypse” concerns — the thesis that conversational AI collapses the value of application front-ends and leaves incumbents holding commoditised data plumbing. That thesis took a $37 billion scalp yesterday when Intuit guided fiscal 2027 revenue below consensus and drew eleven price-target cuts (Section F). Salesforce’s response is to concede the interface and defend the layer underneath it — data, workflow and governance — which is a coherent strategy and also an admission. For a portfolio manager the practical question across the whole enterprise-software complex is now whether a company owns the system of record or merely the screen; the first survives this transition and the second may not.

What to watch:Whether Microsoft, Workday or ServiceNow announce comparable “our stack inside someone else’s assistant” integrations — that would confirm interface concession is becoming the sector’s default posture rather than a Salesforce-specific bet.

9. GE Vernova Forms a Korean HVDC Joint Venture and Rises 2.84% — the Session’s Only Mega-Cap Gainer With a Discrete Catalyst

The core facts:GE Vernova announced an agreement with LS Electric to establish a joint venture, to be named Grid X Technology, in voltage-sourced converter HVDC — the transmission technology at the centre of Korea’s next-generation grid. The venture pairs GE Vernova’s VSC-HVDC technology with LS Electric’s local manufacturing and project-execution capability, covering key equipment supply and joint execution of Korean HVDC projects, with stated intent to pursue overseas markets together. The agreement was signed at CIGRE 2026 in Paris, with LS Electric chairman Koo Ja-kyun and CEO Chae Dae-seok alongside GE Vernova’s electrification CEO Philippe Piron and grid systems integration CEO Johan Bindele. It ties to Korea’s West Coast Energy Highway initiative. Shares closed at $953.09, up 2.84%, on a $253.84 billion market capitalisation.

Why it matters:On a session where the four other mega-cap gainers — Arista +5.92%, Oracle +2.84%, Palantir +2.76%, Dell +2.73% — all moved without a same-day catalyst, this one had a document behind it, which is worth noting on its own about the quality of the AI-infrastructure bid. The substance is that HVDC is the physical bottleneck in the datacentre buildout, not chips: moving gigawatts from where power is generated to where it is consumed is what constrains every hyperscaler siting decision, and there are perhaps four credible VSC-HVDC suppliers globally. Localising manufacture through a Korean partner is how GE Vernova gets access to a market that mandates domestic content, and the same template applies to Japan, India and the EU. Industrials led the sector board today at +0.98% after being the week’s laggard at -1.16%, and this is the kind of order-book news that sustains that reversal rather than a one-day rotation.

What to watch:The first awarded contract value under Grid X Technology, and whether GE Vernova’s electrification backlog disclosure at the next quarter reflects Korean HVDC volume.

10. UBS Cuts SAP to Neutral While Raising Its Price Target 23% — and the Reason Is That the Agent Count Is Not Adding Up

The core facts:UBS analyst Michael Briest downgraded SAP from Buy to Neutral while simultaneously lifting his price target to EUR 201 from EUR 164 — a 23% increase on the downgrade. The rationale is delivery pace against ambition: SAP has 17 AI agents generally available and 15 ramping, against a stated goal of 200 by year-end, and Briest expects a cloud-backlog slowdown in the second half of 2026. The ADR closed at $211.68, down 2.42%; the Frankfurt line fell 3.4% to EUR 179.14. Market capitalisation is $242.08 billion.

Why it matters:Cutting a rating while raising a target is unusual enough to be the signal itself: it says the analyst thinks the shares are worth more than he previously modelled and still expects them to lag, which is a statement about the sector’s re-rating rather than the company’s earnings. Thirty-two agents delivered against two hundred promised is a 16% completion rate with four months to run, and the reason that arithmetic matters beyond SAP is that essentially every enterprise-software incumbent has issued a comparable agent-count commitment as evidence it is not being disintermediated. This is the first time a major bank has scored one of those promises and marked it down. Read it alongside Intuit’s guidance reset yesterday and Salesforce conceding the front-end to Claude today: three separate datapoints in two sessions, all pointing at the same question of whether incumbent software can convert AI ambition into backlog on the timetable it has guided to. The cloud-backlog call is the thing to test, because backlog is where the answer shows up before revenue does.

What to watch:SAP’s current cloud backlog growth rate at its next quarterly release — a deceleration would validate Briest and put the whole cohort’s agent-count guidance under the same scrutiny.

11. Enbridge Buys Salt Creek Midstream’s Delaware Basin Gathering System for $600 Million and Extends Its Permian Export Chain

The core facts:Enbridge announced at 08:42 ET that it will acquire Salt Creek Midstream’s crude gathering business for US$600 million in cash, taking 100% of the Orla and Wink North gathering systems and a 50% interest in Delaware Crossing. The assets comprise roughly 500 miles of Delaware Basin crude gathering with 420,000 b/d of capacity and 350,000 barrels of storage, serving more than 20 producers across approximately 320,000 net dedicated acres with an average remaining contract life of about ten years. The system connects Permian barrels to Enbridge’s Ingleside Energy Center. The company said the transaction is immediately accretive to distributable cash flow and earnings per share, left 2026 guidance unchanged, and expects to close later this year. Enbridge’s market capitalisation is roughly US$108.6 billion; its ordinary shares list directly on the NYSE.

Why it matters:This was the largest confirmed transaction of a session in which no company above $100 billion announced any M&A at all — a genuinely quiet deal tape, verified across five independent wires and EDGAR full-text search. What Enbridge is buying is the wellhead end of a chain it already owns the export end of: Ingleside is the largest crude export terminal in the United States, and gathering acreage with ten-year average contract life feeding directly into it converts third-party barrels into captive throughput. That is the highest-quality form of midstream growth, because it is contracted volume rather than commodity exposure, which is why the company could leave guidance untouched while calling it immediately accretive. The strategic read for the sector is that Permian consolidation has moved down the value chain from producers to the gathering systems that serve them, and that US crude export infrastructure is being bid for at a moment when Hormuz transit is running at a third of normal volumes.

What to watch:Enbridge’s Ingleside throughput disclosure after close, and whether Plains, Targa or Energy Transfer respond with competing Delaware Basin gathering acquisitions.

12. Eli Lilly Falls 3.59% and Merck 2.14% as the Obesity Reimbursement Overhang Meets a Rebate-Quality Problem

The core facts:Eli Lilly closed at $1,189.41, down 3.59%, and Merck at $153.10, down 2.14% — both underperforming a healthcare sector that fell 0.95%, and both among the session’s five largest mega-cap decliners. The drivers reported for Lilly are profit-taking after recent gains combined with persistent concern over corporate and commercial health-plan reimbursement for obesity treatments, following coverage rollbacks at employers including PepsiCo and Starbucks. Compounding it, management disclosures indicating that Q2 outperformance was aided by non-recurring US rebate and discount adjustments have sharpened analyst concern about growth deceleration and margin compression in the second half. Merck fell despite genuinely positive same-day news — a Merck/Moderna Phase 3 melanoma trial win and an FDA sBLA acceptance for ENFLONSIA. Moderna itself fell 5.46%.

Why it matters:The rebate-adjustment disclosure is the part with lasting consequence. If a meaningful slice of Lilly’s Q2 beat came from non-recurring rebate and discount true-ups rather than volume, then the reported earnings power of the GLP-1 franchise is lower than the print implied, and second-half comparisons get harder at exactly the moment employer coverage is being withdrawn. Those two forces compound rather than offset: shrinking covered lives and lower realised net price per script hit revenue and margin simultaneously. Merck’s session is the more telling signal for the sector, because a company that delivered a Phase 3 win and a regulatory acceptance on the same day still fell 2.14% — when good news cannot lift a name, the selling is positioning rather than fundamentals, and healthcare has run +15.01% over three months and +26.88% over twelve. That is a crowded trade unwinding at the margin, and it is worth watching whether it broadens.

What to watch:Further employer or PBM announcements withdrawing GLP-1 coverage, and Lilly’s next quarterly disclosure of net price realisation versus volume growth in the incretin franchise.

13. UBS Upgrades argenx and Raises Its Target 46% on an $18 Billion Vyvgart Peak-Sales Estimate

The core facts:UBS analyst Xian Deng upgraded argenx from Neutral to Buy and lifted the price target to $1,400 from $960, a 46% increase. The basis is a raised probability-adjusted peak-sales estimate for Vyvgart of roughly $18 billion, against a headline opportunity the analyst frames at $20 billion, with $5.5 billion modelled for myositis subtypes alone versus consensus nearer $2.6 billion — a revision made following Phase 3 ALKIVIA data. Shares closed at $1,047.10, up 2.71%, on a $64.17 billion market capitalisation. The call was corroborated across four outlets.

Why it matters:The interesting number is not the target but the $5.5 billion versus $2.6 billion gap on myositis — a single indication where one bank now models more than double the street. That is the shape of an estimate revision that either drags consensus toward it over two or three quarters or gets marked back down, and it is the most concrete disagreement about a large-cap biotech franchise available today. The broader point for a healthcare allocation is the contrast with the story immediately above: on a session when the sector’s two largest names sold off on reimbursement and rebate-quality concerns, capital was being upgraded into a rare-disease franchise with narrow, high-value indications and no employer-coverage exposure. That is the defensive rotation inside healthcare that a 26.88% twelve-month sector gain tends to produce late — out of volume-driven primary-care franchises and into specialty biologics where payers have no realistic substitution option.

What to watch:Whether other banks revise myositis peak-sales estimates toward UBS’s $5.5 billion over the next two quarters — consensus migration is what converts this from one analyst’s call into a re-rating.

E. ECONOMY WATCH -> TOP

Q2 GDP held at 1.5% growth — a step down from Q1’s 2.1% — while the Fed’s preferred inflation gauge accelerated to 3.7% YoY, undercutting hopes that price pressures were cooling ahead of Warsh’s first Jackson Hole keynote as Fed chair on Friday. Durable goods orders beat headline estimates but only because of an aircraft rebound; stripped of transportation, core capital-goods orders missed, pointing to still-soft business investment. Pantheon Macro flagged a consumer slowdown gathering steam as the tax-refund cash cushion fades, while a milder-than-expected Iran sanctions package pulled oil down 0.6%, offering a rare disinflationary offset. The mix leaves the Fed little room to ease.

F. EARNINGS WATCH -> TOP

YESTERDAY AFTER THE BELL (Markets Reacted Today)

TODAY BEFORE THE BELL (Markets Already Reacted)

No major earnings before the bell from companies with >$100B market cap. The largest BMO reporter on today’s calendar was Williams-Sonoma (WSM) at a $27.96B market capitalisation, roughly a quarter of the inclusion threshold. No ADR above $100B reported before the bell either, so nothing was excluded on ADR grounds.

TODAY AFTER THE BELL (Markets React Tomorrow)

WEEK AHEAD PREVIEW:

G. WHAT’S NEXT -> TOP

UPCOMING RELEASES:

KEY QUESTIONS:

H. CHART OF THE DAY -> TOP

Market Intelligence Brief (MIB) Ver. 19.28
For professional investors only. Not investment advice.

© 2026 RecessionALERT.com